Ascione A, Claar G M, Gigliotti T, Oriani G A, D'Alessandro R, Cataldi V
Quad Sclavo Diagn. 1975 Jun;11(2):567-77.
43 subjects, affected by chronic aggressive hepatitis (CAH) have been divided into two groups according to the presence of HBAg. No statistically significant differences between the two groups have been provided. The two classes of subjects (HBAg + and -) were also divided into the already treated (with immunosuppressive drugs) and untreated to investigate the eventual differences existing between the two classes. The results of this division was that previously treated subjects present a lower total bilirubin (P less than 0.05) in respect to those that were not treated previously. The results of all the other comparisons carried out and the tested correlations were negligible. In conclusion, bearing in mind the inadequate methods used up to now to research the HBAg, the transversal studies show that CAH patients are both affected by the same syndrome, whether the HBAg is positive or negative. However, it is probable that it is not the carrier state of HBAg which enables the liver disease evolution but the liver disease itself enables the cellular immunity disorders that often appear in the course of CAH.
43名慢性侵袭性肝炎(CAH)患者根据乙肝表面抗原(HBAg)的有无分为两组。两组之间未发现统计学上的显著差异。这两类患者(HBAg阳性和阴性)又被分为已接受治疗(使用免疫抑制药物)和未接受治疗两组,以研究这两类患者之间可能存在的差异。结果显示,与未接受过治疗的患者相比,之前接受过治疗的患者总胆红素水平较低(P<0.05)。所有其他比较结果及检测的相关性均无显著意义。总之,鉴于目前用于研究HBAg的方法并不完善,横向研究表明,无论HBAg阳性或阴性,CAH患者均受同一综合征影响。然而,很可能并非HBAg的携带状态导致肝病进展,而是肝病本身导致了CAH病程中经常出现的细胞免疫紊乱。